Generic or, more accurately, follow-on (FO) versions of biological and non-biological complex drugs (NBCD) for multiple sclerosis (MS) are expected to become increasingly available. Incorporation of FO disease-modifying therapy (DMT) requires prioritizing patient safety and drug efficacy, while still addressing practical needs around cost-effectiveness to maximize healthcare access without compromising innovation.